Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A susceptibility gene signature for ERBB2-driven mammary tumour development and metastasis in collaborative cross mice.

EBioMedicine - 1 Aug 2024

Yang Hui, Wang Xinzhi, Blanco-Gómez Adrián, He Li, García-Sancha Natalia, Corchado-Cobos Roberto, Pérez-Baena Manuel Jesús, Jiménez-Navas Alejandro, Wang Pin, Inman Jamie L, Snijders Antoine M, Threadgill David W, Balmain Allan, Chang Hang, Perez-Losada Jesus, Mao Jian-Hua

Abstract excerpt

BACKGROUND: Deeper insights into ERBB2-driven cancers are essential to develop new treatment approaches for ERBB2+ breast cancers (BCs). We employed the Collaborative Cross (CC) mouse model to unearth genetic factors underpinning Erbb2-driven mammary tumour development and metastasis. METHODS: 732 F1 hybrid female mice between FVB/N MMTV-Erbb2 and 30 CC strains were monitored for mammary tumour phenotypes. GWAS...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Disease Models, Animal

Share to Gene Expression Profiling

Share to Gene Expression Regulation, Neoplastic

Share to Neoplasm Metastasis

Share to Receptor, ErbB-2

Share to Transcriptome

Source

Open in PubMed Open full text

Identifiers

PMID: 39067134
DOI: 10.1016/j.ebiom.2024.105260
PMCID: PMC11338061

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A susceptibility gene signature for ERBB2-driven mammary tumour development and metastasis in collaborative cross mice.PMID 39067134Read ↗

A susceptibility gene signature for ERBB2-driven mammary tumor development and metastasis in Collaborative Cross mice with human translational valueSemantic proximity Read ↗

Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterpartsSemantic proximity Read ↗

Determining susceptibility loci in triple negative breast cancer using a novel pre-clinical modelSemantic proximity Read ↗

Integrative multi-omic sequencing reveals the MMTV-Myc mouse model mimics human breast cancer heterogeneitySemantic proximity Read ↗

A Novel Mouse Model that Recapitulates the Heterogeneity of Human Triple Negative Breast CancerSemantic proximity Read ↗

Investigating the genomic landscape of mouse models of breast cancer metastasisSemantic proximity Read ↗

Identification of susceptibility loci using a novel murine model for triple-negative breast cancer.Semantic proximity Read ↗

Cross-Species and Tissue-Agnostic Prediction of Human Cancer Treatment Response using AI-Powered Cellular Morphometric Biomarkers from a Genetically Diverse Erbb2 Mouse ModelSemantic proximity Read ↗

Integrative multi-omic sequencing reveals the MMTV-Myc mouse model mimics human breast cancer heterogeneity.Semantic proximity Read ↗

Genetic Dissection of Cancer Development, Therapy Response, and Resistance in Mouse Models of Breast Cancer.Semantic proximity Read ↗

Modeling Heterogeneity of Triple-Negative Breast Cancer Uncovers a Novel Combinatorial Treatment Overcoming Primary Drug ResistanceSemantic proximity Read ↗

Modeling Heterogeneity of Triple‐Negative Breast Cancer Uncovers a Novel Combinatorial Treatment Overcoming Primary Drug ResistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.